XORTX Therapeutics Inc. Common Shares

GRI Bio, Inc.

Supernus Pharmaceuticals, Inc.

Eikon Therapeutics, Inc.

Candel Therapeutics, Inc.

Compass Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Cartesian Therapeutics, Inc.

Annovis Bio, Inc.

Dilution score: 71/100 (HIGH), None months cash

13F fund flow: neutral, ? institutional managers

Short interest: 1.83% of float, squeeze risk: LOW

SW convergence: 50/100 (Neutral), 0 bullish / 1 bearish signals

<article class="bts-verified-summary" data-ticker="XRTX">
<p>XORTX Therapeutics Inc. Common Shares (XRTX) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>No Form 4 insider filings for XRTX were recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0001729214 (2026-06-17) <a href="https://efts.sec.gov/LATEST/search-index?q=%22XRTX%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-05-18&amp;enddt=2026-06-17" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

SEC EDGAR — 0001729214

XORTX Therapeutics Inc. Common Shares (XRTX) — BioTechSigns Verified Summary

XORTX Therapeutics Inc. Common Shares (XRTX) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.

No Form 4 insider filings for XRTX were recorded at the SEC in the past 30 days[1].

Sources:
[1] SEC EDGAR, 0001729214. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://efts.sec.gov/LATEST/search-index?q=%22XRTX%22&forms=4&dateRange=custom&startdt=2026-05-18&enddt=2026-06-17